CNR2 and cancer: In this study, we demonstrate that the antigen-binding domains of Cetuximab, Enfortumab, and Sacituzumab—originally employed as ADCs for the targeted delivery of cytotoxic agents to cancer cells [30,31]—can also be used to generate cysteine-modified antibodies as vehicles for intracellular transport of the photosensitizer dye WB692-CB2 in PIT.